



1 April 2021

Creso launches three new CBD tea products utilising new technology

Highlights:

- Creso Pharma launches three new CBD based tea products under established and recognised cannaQIX® brand
- New products include: cannaQIX® tea, cannaQIX® NITE tea and cannaQIX® Immunity tea
- Products are based on a 2nd generation newly developed technology optimising CBD content and taste, and provide Creso Pharma with an opportunity to expand its target consumer base into the mainstream convenience food and beverage market.
- Launch follows German Federal Court of Justice ruling annulling charges against tea sellers, opening up the German market for food products based on hemp flowers
- Creso Pharma to sell the tea products to its existing distribution network comprised of over 2,100 points of sale including pharmacies, drugstores and retail chains to consumers in Switzerland, with additional European territories earmarked for near term expansion, including Germany.
- Creso has a proven track record for successful product development and commercialisation, with its cannaQIX® brand of products now available in Switzerland and several European countries.
- Creso Pharma is well funded to further expand proprietary technologies into new verticals, with other value adding initiatives and revenue generating products in human and animal health under development – additional product launches expected shortly

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce the launch of its proprietary CBD-based teas products in Switzerland with other European markets, including Germany, earmarked for near term expansion.

Three new products have been launched under the cannaQIX® brand and include cannaQIX® tea, cannaQIX® NITE tea and cannaQIX® Immunity tea.



cannaQIX® tea



cannaQIX®NITE tea



cannaQIX®Immunity tea



The three new teas have been developed based on a new 2nd generation innovative technology that optimises the CBD content in compliance with regulations and allows for a better taste.

The three tea products include:

- **cannaQIX® tea:** designed to help the management of stress supporting a better quality of life
- **cannaQIX® NITE tea:** to be consumed at night time to support a better sleep.
- **cannaQIX® Immunity tea:** which provides the supplements and taste to optimise well-being.

The development of the new tea products is a ground breaking technological achievement for Creso Pharma and provides the Company with a significant competitive advantage. The Company will now progress the use of the new technology in the manufacturing of its cannaQIX® lozenge flagship products.

Having completed the necessary legal and regulatory due diligence, the new tea products can now be legally marketed and sold throughout Switzerland, leveraging Creso's established distribution network comprised of over 2,100 point of sales across in Switzerland where Creso's cannaQIX® products are already being sold. These include pharmacies, pharmacy networks, drugstores, health nutrition shops and large retail groups including leading department store chain Manor. Creso also supplies all major wholesalers in the country including Galexis, Amedis and Voigt.

This provides the Company with an established footprint, significantly de-risking the launch of each new product it brings to market.

The Company will also look to launch its new hemp tea products in Germany, following a recent decision by the German Federal Court of Justice to annul previous charges against hemp tea sellers which had temporarily delayed the scheduled Q3 2020 roll out of the Company's hemp tea products. The favourable decision has removed ambiguity over the guidelines concerning the sale of food products based on hemp flowers and leaves in Germany, with Creso now being in a position to actively market and sell its hemp tea products in that jurisdiction without any further regulatory approvals or hurdles to overcome.

Upon successful roll out of its new products in Switzerland and Germany, Creso will explore the opportunity to expand the distribution of its hemp tea products into other European companies, and, in line with its standard practices, will undertake the necessary due diligence to confirm the legality of the sale of its products in each new jurisdiction as required.

Creso expects that its new products will be well received by consumers and looks forward to providing further updates in due course.

Management Commentary

Commercial & Development Director Dr Gian Trepp, said: *"We are proud to have completed the finalisation of this ground breaking technology for our new CBD tea products, which opens a number of new and globally applicable opportunities for Creso Pharma. The new products and formulation provide a very tasty CBD tea that will become a key component in the future production of the cannaQIX® lozenges. We look forward to providing further updates on future product additions and our European expansion initiatives."*

Ends-

**Authority and Contact Details**

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.